SCHEMBL2658413

SCHEMBL2658413

CSc1ccc(CO)nc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MBOAT4 Q96T53 1/20 0.40
CCR1 P32246 1/20 0.35
PIK3CA P42336 1/20 0.33
PI4KA P42356 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
S1PR1 P21453 1/20 0.32
GABRA5 P31644 1/20 0.32
SLC6A4 P31645 5/20 0.32
ALDH1A1 P00352 1/20 0.32
NOS3 P29474 2/20 0.31
NOS1 P29475 2/20 0.31
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21770489 0.85 PIK3CA (0.42) PIK3CAPI4KAPI4KBS1PR1SLC6A4
SCHEMBL8126493 0.81 MBOAT4 (0.40) MBOAT4GABRA5SLC6A4ALDH1A1NPC1
SCHEMBL15486819 0.79 MBOAT4 (0.43) MBOAT4GABRA5SLC6A4ALDH1A1NOS3
SCHEMBL23891897 0.79 MBOAT4 (0.40) MBOAT4GABRA5SLC6A4ALDH1A1NPC1
SCHEMBL18724680 0.73 NPSR1 (0.49) ALDH1A1NPC1RAB9A
SCHEMBL21166 0.71
SCHEMBL8441489 0.71
SCHEMBL20928752 0.69 NOS3 (0.37) POLBS1PR1ALDH1A1NOS3NOS1
SCHEMBL25252757 0.69 ALDH1A1 (0.46) POLBALDH1A1TSHRRAB9A
SCHEMBL4140258 0.69 CCR1 (0.41) CCR1PIK3CAPI4KAPI4KBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117083271-A Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors 伊迪亚生物科学有限公司 2023-11-17 CN disclosed
WO-2021121294-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2021-06-24 WO disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
EP-2157859-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE Takeda Pharmaceutical Company Limited (JP) 2010-03-03 EP disclosed
WO-2008156757-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-24 WO disclosed
WO-2008156757-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE GCKR, GCK, KHK MBOAT4 2518/4885CCR1 3733/4885PIK3CA 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.